📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
102 analysed today
FollowTelegram
102
Today
151,964
All-time analysed
43,581
Positive
6,744
Negative
92,799
Neutral
8,772
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
172 announcements match the current filters (relevance ≥ 5).
HILINFRA Reappoints MD & WTD for 3 Years; Proposes Dividend Waiver Clause in AOA
Highway Infrastructure Limited (HILINFRA) has approved the reappointment of Mr. Arun Kumar Jain as Managing Director and Mr. Anoop Agrawal as Whole-Time Director for three-year terms starting May 5, 2026. The board also proposed an amendment to the Articles of Association (Clause 154A) to allow shareholders to voluntarily waive their right to receive dividends. Mr. Jain and Mr. Agrawal bring 31 and 22 years of industry experience respectively to their roles. These proposals are subject to final approval by the company's shareholders.
Key Highlights
Reappointment of Mr. Arun Kumar Jain as Managing Director for a 3-year term effective May 5, 2026.
Reappointment of Mr. Anoop Agrawal as Whole-Time Director for a 3-year term effective May 5, 2026.
Proposed insertion of Clause 154A in the Articles of Association to enable voluntary dividend waivers by members.
MD Mr. Arun Kumar Jain has over 31 years of experience and is a promoter of the company.
WTD Mr. Anoop Agrawal has 22 years of experience and also serves as the Chief Financial Officer.
👀 What to Watch
Investors should note the continuity in leadership as a positive for operational stability. The dividend waiver clause is a technical provision that provides flexibility to large shareholders but does not negatively impact minority rights.
HILINFRA Re-appoints MD and WTD for 3-Year Terms; Amends AOA for Dividend Waiver
Highway Infrastructure Limited has approved the re-appointment of Mr. Arun Kumar Jain as Managing Director and Mr. Anoop Agrawal as Whole-Time Director for three-year terms effective May 5, 2026. Both individuals are promoters with significant experience—31 years and 22 years respectively—in the infrastructure sector. Additionally, the company is amending its Articles of Association to allow shareholders to voluntarily waive their dividend entitlements. These decisions ensure management continuity but remain subject to shareholder approval.
Key Highlights
Re-appointment of Mr. Arun Kumar Jain as Managing Director for a 3-year term starting May 5, 2026.
Re-appointment of Mr. Anoop Agrawal as Whole-Time Director for a 3-year term starting May 5, 2026.
Amendment of AOA Clause 154A to enable shareholders to voluntarily waive their right to receive dividends.
Managing Director Arun Kumar Jain brings over 31 years of experience in the infrastructure sector.
Whole-Time Director Anoop Agrawal has been associated with the company since 2006 with 22 years of experience.
👀 What to Watch
Investors should note the management continuity as a positive for operational stability; no immediate action is required as these are re-appointments of existing promoter-directors.
Highway Infrastructure Amends AOA for Dividend Waiver; Re-appoints MD & WTD for 3 Years
Highway Infrastructure Limited has approved a significant amendment to its Articles of Association (AOA) by inserting Clause 154A, which allows shareholders to voluntarily waive their right to dividends. Additionally, the board has approved the re-appointment of Mr. Arun Kumar Jain as Managing Director and Mr. Anoop Agrawal as Whole-Time Director, both for three-year terms effective May 5, 2026. These leadership roles are critical as Mr. Jain and Mr. Agrawal bring 31 and 22 years of industry experience, respectively. All proposed changes and appointments are subject to the final approval of the company's shareholders.
Key Highlights
Proposed insertion of Clause 154A in AOA to enable voluntary waiver of interim or final dividends by shareholders.
Re-appointment of Promoter Mr. Arun Kumar Jain as Managing Director for a 3-year term starting May 5, 2026.
Re-appointment of Mr. Anoop Agrawal as Whole-Time Director and CFO for a 3-year term starting May 5, 2026.
Mr. Arun Kumar Jain brings over 31 years of experience in the infrastructure sector to the leadership team.
The board meeting commenced at 11:00 AM and concluded at 11:45 AM on June 6, 2026.
👀 What to Watch
Investors should note the continuity in top management as a positive sign for operational stability. The AOA amendment for dividend waiver is a technical provision often used by promoters to retain cash within the company, which warrants monitoring of future dividend payout patterns.
Highway Infrastructure Reports Record ₹1,143 Cr Order Book; FY26 PAT Surges 42% to ₹31.8 Cr
Highway Infrastructure Limited (HILINFRA) reported a robust financial performance for FY26, with total income growing 25.6% YoY to ₹633.4 crores and PAT increasing 42% to ₹31.8 crores. The company achieved its highest-ever order book of ₹1,143 crores, providing strong revenue visibility across its Tollway and EPC segments. Management maintained financial discipline with a low debt-to-equity ratio of 0.45x and an ROE of 18.4%, while strategically exiting non-profitable contracts to protect margins.
Key Highlights
Total income for FY26 rose 25.6% YoY to ₹633.4 crores, with EBITDA growing 28.4% to ₹51.5 crores.
Record order book of ₹1,143 crores as of March 2026, comprising ₹591.3 crores in EPC and ₹526.1 crores in Tollway Collection.
Tollway collection remains the dominant vertical contributing 73.7% of revenue, including the company's largest-ever ₹328.8 crore contract for Kaza Fee Plaza.
Real Estate revenue saw a significant jump to ₹41.6 crores in FY26 from ₹8.0 crores in the previous year.
Company maintains a healthy balance sheet with a debt-to-equity ratio of 0.45x and a Return on Equity (ROE) of 18.4%.
👀 What to Watch
Investors should take note of the record order book and the management's disciplined approach to project selection, which prioritizes profitability over scale. The diversification into wayside amenities and ropeways presents long-term growth catalysts beyond traditional road projects.
Shilpa Medicare to Acquire 30.4% Stake in Gate2Brain for Euro 7 Million
Shilpa Medicare's subsidiary, Shilpa Biocare, is entering a strategic equity partnership to acquire a 30.4% stake in Spanish biotech firm Gate2Brain for Euro 7 million. The deal involves Euro 0.5 million in cash, Euro 5.5 million in equity for services, and Euro 1 million for project development. This partnership focuses on advancing G2B-002, a brain cancer therapy with Orphan Drug Designation from both the US FDA and EMA. Shilpa will serve as the exclusive CMC and manufacturing partner, targeting high-value oncology markets such as Glioblastoma, which is projected to reach USD 6.48 billion by 2035.
Key Highlights
Acquisition of a 30.4% equity stake in Gate2Brain for a total contribution of Euro 7 million.
Lead candidate G2B-002 has received Orphan Drug Designation (ODD) from both the U.S. FDA and EMA.
Investment structure includes Euro 5.5 million as 'equity for services', leveraging Shilpa's manufacturing capabilities.
Proprietary MiniAp4 peptide shuttle technology demonstrated up to 100-fold greater brain drug transport in preclinical models.
First-in-human trials for the lead brain cancer asset are anticipated to commence by FY28.
👀 What to Watch
Investors should monitor the progress of clinical trials for G2B-002 as a long-term value driver, while noting that the 'equity for services' model de-risks the cash outflow for Shilpa Medicare.
Shilpa Medicare Unit VI Receives USFDA Form 483 with 5 Procedural Observations
Shilpa Medicare's Bengaluru facility (Unit VI) underwent a USFDA Pre-Approval Inspection from May 25 to May 29, 2026. The inspection concluded with the issuance of Form 483 containing 5 procedural observations, none of which are related to data integrity or are repeat findings. The facility specializes in oral dispersible films and transdermal patches and already holds VAI status from previous audits. Management expects no material impact on current operations and plans to respond within the stipulated timeline.
Key Highlights
USFDA conducted a Pre-Approval Inspection at the Bengaluru Unit VI from May 25-29, 2026
The inspection resulted in Form 483 with 5 procedural observations and zero data integrity issues
Unit VI holds existing accreditations from EMA (Europe), MHRA (UK), TGA (Australia), and SFDA (Saudi Arabia)
Management confirmed no material impact on current business operations or existing supplies
👀 What to Watch
Investors should monitor the company's response to the USFDA and the final classification of the audit. The absence of data integrity issues suggests a lower risk of severe regulatory action like a Warning Letter.
Hilton Metal Forging Approves FY26 Audited Financial Results with Unmodified Audit Opinion
Hilton Metal Forging Limited's Board of Directors approved the audited standalone financial results for the quarter and full year ended March 31, 2026, during their meeting on May 29, 2026. The statutory auditors, M/s. Anil Bansal & Associates, issued an audit report with an unmodified opinion, signaling no significant accounting concerns. Along with financial results, the board also approved the Management Discussion Analysis and Corporate Governance reports for the fiscal year. While the specific profit and loss figures were not detailed in this cover letter, the clean audit report ensures the reliability of the forthcoming detailed statements.
Key Highlights
Board approved audited standalone financial results for the quarter and year ended March 31, 2026.
Statutory auditors issued an audit report with an unmodified opinion for the financial year.
Management Discussion Analysis (MDA) and Corporate Governance Report for FY 2025-26 were formally approved.
The board meeting was held on May 29, 2026, commencing at 5:00 P.M. and concluding at 7:30 P.M.
👀 What to Watch
Investors should review the detailed financial tables once released to assess year-on-year growth in revenue and margins. The unmodified audit opinion is a positive indicator of financial reporting integrity.
HILINFRA FY26 PAT Grows 42% YoY to ₹31.8 Cr; Order Book Hits Record ₹1,133 Cr
Highway Infrastructure Limited (HIL) reported a strong full-year performance for FY26 with a 42% YoY increase in PAT to ₹31.8 crore and a 25.6% rise in total income to ₹633.4 crore. While Q4FY26 revenue more than doubled to ₹277.2 crore, quarterly PAT declined by 27.5% YoY due to higher input costs impacting margins. The company's order book surged 113% YoY to a record ₹1,133 crore, providing significant revenue visibility. The balance sheet remains robust with a debt-to-equity ratio of 0.45x and a healthy ROE of 18.4%.
Key Highlights
FY26 Consolidated Revenue grew 25.6% YoY to ₹633.4 crore, while PAT rose 42% to ₹31.8 crore.
Order book reached a record ₹1,133 crore as of March 2026, representing a 113% increase YoY.
Q4FY26 revenue spiked 104.4% YoY to ₹277.2 crore, though EBITDA margins contracted to 5.8% from 13.8% in the previous year's quarter.
Net worth increased by 94% YoY to ₹228.5 crore, significantly strengthening the balance sheet.
The company maintained a healthy Return on Equity (ROE) of 18.4% for the full year FY26.
👀 What to Watch
Investors should view the record order book as a strong catalyst for future growth, though the recent margin compression in Q4 due to input costs warrants monitoring in upcoming quarters.
Rushil Decor FY26 PAT Plummets 86.7% to ₹64M Amid Operational Disruptions
Rushil Decor reported a challenging FY2026 with consolidated revenue declining 4% YoY to ₹8,622 million and PAT dropping sharply by 86.7% to ₹64 million. The performance was severely impacted by a fire incident at the Andhra Pradesh MDF facility, elevated resin prices, and geopolitical uncertainties affecting exports. However, Q4 FY26 showed signs of recovery with adjusted EBITDA growing 18.6% YoY to ₹286 million. To counter margin pressure, the company implemented significant price hikes of 15% in MDF and 10% in Laminates effective April 2026.
Key Highlights
FY26 Consolidated Revenue fell 4% YoY to ₹8,622 million, while PAT crashed 86.7% to ₹64 million.
MDF segment revenue declined 8.2% YoY to ₹6,091 million with capacity utilization dropping to 75% for the year.
Laminates segment grew 6.1% YoY to ₹2,111 million, supported by a 21% growth in domestic laminate revenue.
Implemented price hikes of 15% for MDF and 10% for Laminates starting April 1, 2026, to offset inflationary pressures.
Targeting value-added products to contribute 60% of MDF revenue and 50% of volumes by FY2027.
👀 What to Watch
Investors should closely monitor the effectiveness of the April 2026 price hikes in restoring margins and the ramp-up of the high-margin Jumbo Laminates facility. While the full-year profit decline is concerning, the sequential improvement in Q4 EBITDA suggests the worst may be over.
Rushil Decor Q4 EBITDA Up 18.6% YoY to ₹286 Mn; FY26 PAT Declines 86.7%
Rushil Decor reported a recovery in Q4 FY26 with EBITDA growing 18.6% YoY to ₹286 million, despite flat revenue of ₹2,309 million. However, the full-year FY26 performance was severely impacted by a fire at the Andhra Pradesh MDF facility and high resin costs, resulting in an 86.7% drop in annual PAT to ₹64 million. To mitigate inflationary pressures, the company implemented significant price hikes of 10-15% across its product portfolio effective April 1, 2026. Management is now focusing on scaling the new Jumbo Laminates facility and improving capacity utilization.
Key Highlights
Q4 FY26 EBITDA increased 18.6% YoY to ₹286 million with margins expanding to 12.4%.
Full-year FY26 PAT fell 86.7% to ₹64 million due to operational disruptions and a fire incident.
Laminates segment saw 21% YoY growth in domestic revenue for FY26.
Implemented price hikes of 15% in MDF and 10% in Laminates starting April 2026.
Maintained a stable balance sheet with a Net Debt to Equity ratio of 0.39x.
👀 What to Watch
Investors should monitor if the April 2026 price hikes successfully restore full-year profitability without hurting volumes. The Q4 margin recovery is a positive sign, but the stock remains a 'watch' until the impact of the fire incident is fully behind the company and Jumbo Laminate exports scale up.
Rushil Decor Recommends ₹0.05 Final Dividend and Approves FY26 Audited Results
Rushil Decor Limited's Board has recommended a final dividend of ₹0.05 per equity share (5% of face value ₹1) for the financial year 2025-26. The company reported standalone revenue from operations of ₹2,303.81 million for the quarter ended March 31, 2026, compared to ₹2,152.25 million in the previous quarter. Total income for Q4 FY26 stood at ₹2,340.77 million with an unmodified audit opinion. Additionally, the board has appointed M/s. G. B. & Co. as the internal auditors for the 2026-27 financial year.
Key Highlights
Recommended a final dividend of ₹0.05 per equity share of face value ₹1 (5%) for FY 2025-26.
Standalone Revenue from operations for Q4 FY26 reported at ₹2,303.81 million.
Total income for the quarter ended March 31, 2026, rose to ₹2,340.77 million from ₹2,160.42 million in Q3 FY26.
Statutory auditors issued an unmodified opinion on the annual financial results.
Appointment of M/s. G. B. & Co. as Internal Auditors for the financial year 2026-27.
👀 What to Watch
The dividend yield is relatively low at 5% of the face value; investors should focus on the underlying earnings growth and operational margins in the full audited report. Monitor the upcoming Annual General Meeting for the announcement of the dividend record date.
Rushil Decor Q4 FY26 Results: Revenue at ₹2,303.8M, Recommends ₹0.05 Final Dividend
Rushil Decor Limited reported a sequential increase in revenue from operations to ₹2,303.81 million for the quarter ended March 31, 2026, up from ₹2,152.25 million in the previous quarter. The Board has recommended a final dividend of ₹0.05 per equity share (5% of face value) for the financial year 2025-26. Additionally, the company has appointed M/s. G. B. & Co. as Internal Auditors for FY 2026-27. The statutory auditors have issued an unmodified opinion on the financial results, indicating transparency in reporting.
Key Highlights
Revenue from operations grew to ₹2,303.81 million in Q4 FY26 from ₹2,152.25 million in Q3 FY26.
Recommended a final dividend of ₹0.05 per equity share (5%) on a face value of ₹1.
Total income for the quarter stood at ₹2,340.77 million including other income of ₹36.96 million.
Appointment of M/s. G. B. & Co. as Internal Auditors for the 2026-27 financial year.
Statutory auditors provided an unmodified opinion for both standalone and consolidated results.
👀 What to Watch
Investors should note the steady sequential revenue growth and the dividend payout as signs of stability. Monitor the upcoming Annual General Meeting for the record date and final approval of the dividend.
Highway Infrastructure Limited Approves FY26 Audited Results and Appoints New Auditors
Highway Infrastructure Limited (HILINFRA) has approved its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The statutory auditors issued an unmodified opinion, indicating that the financial statements provide a true and fair view of the company's performance. The board also recommended the appointment of M/s Ritesh Gupta & Co. as Secretarial Auditor for a five-year term and appointed Mr. Sachin Kumar Jain as Internal Auditor for FY 2026-27. Notably, the company reported no deviations in the utilization of proceeds from its Initial Public Offering (IPO).
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Statutory auditors M/s. Anil Kamal Garg & Company issued an unmodified audit opinion for the fiscal year.
Confirmed zero deviation or variation in the utilization of funds raised through the company's IPO.
Proposed appointment of M/s Ritesh Gupta & Co. as Secretarial Auditor for a 5-year tenure starting from the upcoming AGM.
Appointed Mr. Sachin Kumar Jain as Internal Auditor for FY 2026-27 to oversee internal financial controls.
👀 What to Watch
Investors should monitor the full financial statement for specific revenue and margin trends once the detailed tables are fully analyzed. The clean audit report and adherence to IPO fund utilization are positive indicators of corporate governance.
Shilpa Medicare Reports Record FY26 Revenue of ₹1,549 Cr; Adjusted PAT Surges 135% YoY
Shilpa Medicare delivered a strong FY26 performance with record revenues of ₹1,549 crores and an EBITDA of ₹445 crores, driven by robust growth in formulations and biologics. The company's adjusted PAT grew by 135% to ₹232 crores, while adjusted ROCE improved significantly to 17.4% from 4% in FY23. Management is pivoting towards complex products, including ADCs and biosimilars, with key launches like Aflibercept and Rotigotine planned for FY27.
Key Highlights
Full-year FY26 revenue grew 18% to ₹1,549 crores, with Q4 revenue hitting a record ₹439 crores.
Adjusted PAT (excluding exceptional gains) jumped 135% YoY to ₹232 crores for the full year.
Formulation business (excluding licensing) grew 75% for the year, with European revenues doubling to over ₹200 crores.
Biologics segment revenue doubled to ₹150 crores, supported by strong CDMO deal momentum.
Adjusted ROCE improved from 4% in FY23 to 17.4% in FY26, reflecting significantly better operating leverage.
👀 What to Watch
Investors should monitor the successful commercialization of high-value products like Aflibercept and Rotigotine in FY27. The company's transition to a complex formulation and biologics platform supports long-term margin expansion and justifies a positive outlook.
Shilpa Medicare FY26 Revenue Grows 18% to ₹1,549 Cr; Adj. PAT Surges 135%
Shilpa Medicare reported a strong financial performance for FY26, with consolidated revenue reaching INR 1,549 crores, an 18% YoY increase. The company's profitability saw a significant boost, with EBITDA growing 30% to INR 445 crores and Adjusted PAT surging 135% to INR 232 crores. The Formulations segment was a key growth driver, increasing 30% YoY to INR 618 crores, supported by the successful launch of NorUDCA for NAFLD. Operational efficiency improved as EBITDA margins expanded to 29% and the Net Debt to EBITDA ratio decreased to 1.4x.
Key Highlights
FY26 Revenue grew 18% YoY to INR 1,549 crores; Q4 FY26 revenue rose 30% to INR 439 crores.
Adjusted PAT for FY26 increased by 135% YoY to INR 232 crores, demonstrating strong bottom-line acceleration.
EBITDA margins expanded by 300 bps to 29% for FY26, driven by a favorable product mix and operating leverage.
Formulations revenue grew 30% YoY in FY26, with EU revenue crossing the INR 200 crore milestone.
Net Debt to EBITDA ratio improved from 1.6x in FY25 to 1.4x in FY26, reflecting better capital efficiency.
👀 What to Watch
Investors should note the strong turnaround in profitability and the scaling of high-margin formulations and biologics segments. The stock remains a positive watch given the upcoming transdermal patch launches in the EU and US.
Shilpa Medicare Recommends ₹0.60 Dividend and 28% Stake Acquisition in Neo Green Power
Shilpa Medicare's board has recommended a final dividend of ₹0.60 per share (60% of face value) for the financial year 2025-26. In a strategic move, the company's subsidiaries will also acquire a 28% equity stake in Neo Green Power Project Private Limited for ₹4.44 crore to meet captive renewable energy requirements. Additionally, the company has approved its audited FY26 financial results and proposed shifting its registered office from Karnataka to Maharashtra. These developments indicate a focus on shareholder returns and operational cost optimization through green energy.
Key Highlights
Recommended a final dividend of ₹0.60 (60%) per equity share of face value ₹1 for FY 2025-26.
Subsidiaries to acquire a 28% stake in Neo Green Power Project Private Limited for ₹4.44 crore.
The acquisition is intended to secure renewable energy for captive power consumption in subsidiaries.
Approved audited standalone and consolidated financial statements for FY ended March 31, 2026.
Proposed shifting of the registered office from Raichur, Karnataka to the State of Maharashtra.
👀 What to Watch
Investors should monitor the upcoming AGM for dividend approval and the impact of the renewable energy investment on long-term operating margins. The shift to Maharashtra suggests a strategic relocation to a major industrial hub which may offer better administrative synergies.
Shilpa Medicare Recommends 60% Dividend; To Acquire 28% Stake in Neo Green Power
Shilpa Medicare has recommended a final dividend of Re. 0.60 per share for FY 2025-26, representing 60% of the face value. The company is also investing ₹4.44 Crore for a 28% stake in Neo Green Power Project Private Limited to meet captive energy needs for its subsidiaries. Furthermore, the board approved shifting the registered office from Karnataka to Maharashtra, subject to shareholder approval. These moves indicate a focus on operational efficiency through renewable energy and corporate restructuring.
Key Highlights
Recommended a final dividend of Re. 0.60 (60%) per equity share of face value Re. 1 for FY 2025-26.
Investing ₹4.44 Crore to acquire a 28% equity stake in Neo Green Power Project Private Limited.
The acquisition is intended for captive power consumption to optimize energy costs across subsidiaries.
Approved shifting the registered office and those of four wholly-owned subsidiaries from Karnataka to Maharashtra.
Appointed M/s ANEJA ASSOCIATES as Internal Auditors and M/s. V.J. Talati & Co. as Cost Auditors for FY 2026-27.
👀 What to Watch
The dividend and strategic investment in renewable energy are positive signals for long-term cost management. Investors should maintain their positions while monitoring the impact of the corporate relocation on administrative efficiency.
Rushil Decor Delays Restart of Mansa Laminate Plant by 10-15 Days
Rushil Decor Limited has announced a further delay in the resumption of operations at its laminate manufacturing unit in Mansa, Gujarat. The plant, which was undergoing a planned technological upgradation since early April 2026, has faced technical hurdles during the restart process. The company now estimates that regular commercial operations will take an additional 10 to 15 days to commence. This follows previous updates on April 1 and April 20, indicating a longer-than-anticipated downtime for this facility.
Key Highlights
Mansa, Gujarat laminate plant restart delayed by approximately 10-15 days.
Delay is attributed to technical reasons encountered during the technological upgradation phase.
The plant has been under shutdown/upgradation since the first week of April 2026.
This is the third regulatory update regarding the timeline of this specific manufacturing unit's upgrade.
👀 What to Watch
Investors should monitor the company's next filing to confirm if production resumes within the new 15-day window. While the delay is short-term, repeated extensions could marginally impact the quarterly production volumes for the laminate segment.
Shilchar Tech Wins GST Appeal; ₹3.17 Crore Tax Demand Set Aside
Shilchar Technologies has received a favorable order from the Commissioner of Central Tax (Appeals) regarding a prior GST demand. The appellate authority has set aside a demand of ₹3.17 crore out of an original total demand of ₹3.19 crore issued in March 2026. While a portion of the set-aside amount (₹1.64 crore) is to be re-determined under Section 73 of the CGST Act, the associated interest and penalties have also been cancelled. The company confirms that this order will not have a material impact on its financial position or operations.
Key Highlights
Appellate authority set aside ₹3,17,73,217 out of a total ₹3,19,24,454 GST demand
Interest and penalty equivalent to the set-aside tax demand have also been cancelled
Order directs re-determination of ₹1,64,50,315 under Section 73 instead of Section 74 of the CGST Act
The company maintains there is no material impact on financial or operational activities
👀 What to Watch
Investors should view this as a positive development as it significantly reduces a potential tax liability and associated penalties. Monitor the final re-determination of the ₹1.64 crore portion for any minor residual impact.
Shilchar Technologies FY26 PAT up 8% to ₹158 Cr; Targets ₹800 Cr Revenue in FY27
Shilchar Technologies reported FY26 revenue of ₹652 crores, a 5% YoY growth, with a PAT of ₹158 crores. While Q4 FY26 was weak due to deferred Middle East shipments and US tariff uncertainties, management has provided a strong revenue guidance of ₹800 crores for FY27. The company remains debt-free with ₹246 crores in cash and is doubling its capacity to 14,000 MVA by April 2027. Despite Q4 margin compression to 21%, the long-term compounding story remains intact with a 5-year PAT CAGR of 83%.
Key Highlights
FY26 Revenue grew 5% YoY to ₹652 crores with an annual EBITDA margin of 29%.
Q4 FY26 performance was hit by deferred exports worth ₹35-40 crores due to Middle East logistics issues.
Management targets ₹800 crores revenue for FY27, supported by a current order book of ₹452 crores.
Ongoing ₹120 crore capex to increase capacity to 14,000 MVA is on track for April 2027 commissioning.
Company maintains a strong balance sheet with zero debt and cash reserves of ₹246 crores.
👀 What to Watch
Investors should watch for the realization of deferred export revenue in Q1 FY27 to confirm margin recovery. The company's capacity expansion and strong presence in the renewable energy sector make it a solid long-term bet, though short-term volatility in raw material costs should be monitored.
